# Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer

> **NCT07636798** · PHASE1,PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** HAIC Combined Regimen Treatment Group

## Key facts

- **NCT ID:** NCT07636798
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2029-03
- **Final completion:** 2029-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07636798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07636798, "Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07636798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*